Answers are grounded in this paper and cite their sources.
Neurorehabilitation is an exposure-rich intervention in which treatment dose, behavioral practice, neuromodulation, and environmental conditions act on biologically heterogeneous patients. We conducted a scoping review of same-study evidence linking genetic, epigenetic, or molecular factors with rehabilitation, lifestyle, or exposome-related exposures and recovery outcomes. Searches identified 21 eligible studies, predominantly in stroke, with smaller multiple sclerosis and traumatic brain injury clusters. Candidate-gene analyses, especially brain-derived neurotrophic factor (BDNF) Val66Met, dominated a heterogeneous literature with domain-specific, mixed, or null findings. Current evidence does not support routine genotype-based treatment selection. We propose a four-level research architecture linking biological state, measurable exposures, circuit engagement, and recovery phenotypes. This framework is not a validated clinical decision tool. Its nearer-term purpose is to guide exposure measurement and mechanistic trial design, with prospective interaction testing and external validation required before clinical use.
No takes yet. Share an insight, caveat, or question.
Calabrò et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: